tbuckley/cabot-search huggingface dataset:
What should all health professionals know about movement behaviour change? An international Delphi-based consensus statement
Authors: Tahlia Alsop, Emily Lehman, Sandra Brauer, Roma Forbes, Coral L Hanson, Genevieve Healy, Karen Milton, Hamish Reid, Ingrid Rosbergen, Sjaan Gomersall
Journal: British Journal of Sports Medicine (2023)

The WHO has called for action to integrate physical activity promotion into healthcare settings, yet there is a lack of consensus on the competencies required by health professionals to deliver effective movement behaviour change support. The objective of this study was to establish key competencies relevant for all health professionals to support individuals to change their movement behaviours. Consensus was obtained using a three-phase Delphi process. Participants with expertise in physical activity and sedentary behaviour were asked to report what knowledge, skills and attributes they believed health professionals should possess in relation to movement behaviour change. Proposed competencies were developed and rated for importance. Participants were asked to indicate agreement for inclusion, with consensus defined as group level agreement of at least 80%. Participants from 11 countries, working in academic (55%), clinical (30%) or combined academic/clinical (13%) roles reached consensus on 11 competencies across 3 rounds (n=40, n=36 and n=34, respectively). Some competencies considered specific to certain disciplines did not qualify for inclusion. Participants agreed that health professionals should recognise, take ownership of, and practise interprofessional collaboration in supporting movement behaviour change; support positive culture around these behaviours; communicate using person-centred approaches that consider determinants, barriers and facilitators of movement behaviours; explain the health impacts of these behaviours; and recognise how their own behaviour influences movement behaviour change support. This consensus defines 11 competencies for health professionals, which may serve as a catalyst for building a culture of advocacy for movement behaviour change across health disciplines.
Prebiotic diet changes neural correlates of food decision-making in overweight adults: a randomised controlled within-subject cross-over trial
Authors: Evelyn Medawar, Frauke Beyer, Ronja Thieleking, Sven-Bastiaan Haange, Ulrike Rolle-Kampczyk, Madlen Reinicke, Rima Chakaroun, Martin von Bergen, Michael Stumvoll, Arno Villringer, A Veronica Witte
Journal: Gut (2023)

Animal studies suggest that prebiotic, plant-derived nutrients could improve homoeostatic and hedonic brain functions through improvements in microbiome-gut-brain communication. However, little is known if these results are applicable to humans. Therefore, we tested the effects of high-dosed prebiotic fibre on reward-related food decision-making in a randomised controlled within-subject cross-over study and assayed potential microbial and metabolic markers.
Erythropoietin downregulates red blood cell clearance, increasing transfusion efficacy in severely anemic recipients
Authors: Madeleine Casimir, Martin Colard, Michael Dussiot, Camille Roussel, Anaïs Martinez, Carole Peyssonnaux, Patrick Mayeux, Samantha Benghiat, Sandra Manceau, Anne Francois, Nathalie Marin, Frédéric Pène, Pierre A. Buffet, Olivier Hermine, Pascal Amireault
Journal: American Journal of Hematology (2023)

Abstract Red blood cells (RBC) transfusion is used to alleviate symptoms and prevent complications in anemic patients by restoring oxygen delivery to tissues. RBC transfusion efficacy, that can be measured by a rise in hemoglobin (Hb) concentration, is influenced by donor‐, product‐, and recipient‐related characteristics. In some studies, severe pre‐transfusion anemia is associated with a greater than expected Hb increment following transfusion but the biological mechanism underpinning this relationship remains poorly understood. We conducted a prospective study in critically ill patients and quantified Hb increment following one RBC transfusion. In a murine model, we investigated the possibility that, in conjunction with the host erythropoietic response, the persistence of transfused donor RBC is improved to maintain a highest RBC biomass. We confirmed a correlation between a greater Hb increment and a deeper pre‐transfusion anemia in a cohort of 17 patients. In the mouse model, Hb increment and post‐transfusion recovery were increased in anemic recipients. Post‐transfusion RBC recovery was improved in hypoxic mice or those receiving an erythropoiesis‐stimulating agent and decreased in those treated with erythropoietin (EPO)‐neutralizing antibodies, suggesting that EPO signaling is necessary to observe this effect. Irradiated recipients also showed decreased post‐transfusion RBC recovery. The EPO‐induced post‐transfusion RBC recovery improvement was abrogated in irradiated or in macrophage‐depleted recipients, but maintained in splenectomized recipients, suggesting a mechanism requiring erythroid progenitors and macrophages, but which is not spleen‐specific. Our study highlights a physiological role of EPO in downregulating post‐transfusion RBC clearance, contributing to maintain a vital RBC biomass to rapidly cope with hypoxemia.
Deciphering clonal architecture and evolutionary dynamics of secondary acute myeloid leukemia and donor‐derived myelodysplastic syndrome using single‐cell multi‐omics analysis
Authors: Meng‐Ta Sung, Lo‐Ho Chen, Ya‐Wen Chiang, Jie‐Yang Jhuang, Yu‐Chen Chang, Gon‐Shen Caleb Chen, Ken‐Hong Lim
Journal: American Journal of Hematology (2023)

Deciphering clonal architecture and evolutionary dynamics of secondary acute myeloid leukemia and donor-derived myelodysplastic syndrome
Immune cell kinetics and antibody response in<scp>COVID</scp>‐19 patients with low‐count monoclonal B‐cell lymphocytosis
Authors: Guillermo Oliva‐Ariza, Blanca Fuentes‐Herrero, Quentin Lecrevisse, Cristina Carbonell, Alba Pérez‐Pons, Alba Torres‐Valle, Julio Pozo, José Ángel Martín‐Oterino, Óscar González‐López, Amparo López‐Bernús, Marta Bernal‐Ribes, Moncef Belhassen‐García, Oihane Pérez‐Escurza, Martín Pérez‐Andrés, Lourdes Vazquez, Guillermo Hernández‐Pérez, Francisco Javier García Palomo, Pilar Leoz, Pilar Costa‐Alba, Elena Pérez‐Losada, Ana Yeguas, Miryam Santos Sánchez, Marta García‐Blázquez, F. Javier Morán‐Plata, Daniela Damasceno, Vitor Botafogo, Noemí Muñoz‐García, Rafael Fluxa, Jacques J. M. van Dongen, Miguel Marcos, Julia Almeida, Alberto Orfao
Journal: American Journal of Hematology (2023)

Low-count monoclonal B-cell lymphocytosis (MBLlo ) has been associated with an underlying immunodeficiency and has recently emerged as a new risk factor for severe COVID-19. Here, we investigated the kinetics of immune cell and antibody responses in blood during COVID-19 of MBLlo versus non-MBL patients. For this study, we analyzed the kinetics of immune cells in blood of 336 COVID-19 patients (74 MBLlo and 262 non-MBL), who had not been vaccinated against SARS-CoV-2, over a period of 43 weeks since the onset of infection, using high-sensitivity flow cytometry. Plasma levels of anti-SARS-CoV-2 antibodies were measured in parallel by ELISA. Overall, early after the onset of symptoms, MBLlo COVID-19 patients showed increased neutrophil, monocyte, and particularly, plasma cell (PC) counts, whereas eosinophil, dendritic cell, basophil, and lymphocyte counts were markedly decreased in blood of a variable percentage of samples, and with a tendency toward normal levels from week +5 of infection onward. Compared with non-MBL patients, MBLlo COVID-19 patients presented higher neutrophil counts, together with decreased pre-GC B-cell, dendritic cell, and innate-like T-cell counts. Higher PC levels, together with a delayed PC peak and greater plasma levels of anti-SARS-CoV-2-specific antibodies (at week +2 to week +4) were also observed in MBLlo patients. In summary, MBLlo COVID-19 patients share immune profiles previously described for patients with severe SARS-CoV-2 infection, associated with a delayed but more pronounced PC and antibody humoral response once compared with non-MBL patients.
An inhibitory circuit-based enhancer of DYRK1A function reverses Dyrk1a-associated impairment in social recognition
Authors: Yu-Tzu Shih, Jason Bondoc Alipio, Amar Sahay
Journal: Neuron (2023)

Heterozygous mutations in the dual-specificity tyrosine phosphorylation-regulated kinase 1a (Dyrk1a) gene define a syndromic form of autism spectrum disorder. The synaptic and circuit mechanisms mediating DYRK1A functions in social cognition are unclear. Here, we identify a social experience-sensitive mechanism in hippocampal mossy fiber-parvalbumin interneuron (PV IN) synapses by which DYRK1A recruits feedforward inhibition of CA3 and CA2 to promote social recognition. We employ genetic epistasis logic to identify a cytoskeletal protein, ABLIM3, as a synaptic substrate of DYRK1A. We demonstrate that Ablim3 downregulation in dentate granule cells of adult heterozygous Dyrk1a mice is sufficient to restore PV IN-mediated inhibition of CA3 and CA2 and social recognition. Acute chemogenetic activation of PV INs in CA3/CA2 of adult heterozygous Dyrk1a mice also rescued social recognition. Together, these findings illustrate how targeting DYRK1A synaptic and circuit substrates as "enhancers of DYRK1A function" harbors the potential to reverse Dyrk1a haploinsufficiency-associated circuit and cognition impairments.
Blood <scp>CD62L<sup>low</sup></scp> inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab
Authors: Alessandra Vultaggio, Matteo Accinno, Emanuele Vivarelli, Valentina Mecheri, Giandomenico Maggiore, Lorenzo Cosmi, Paola Parronchi, Olivero Rossi, Enrico Maggi, Oreste Gallo, Andrea Matucci
Journal: Allergy (2023)

Abstract Background Eosinophils have been divided into different subpopulations with distinct phenotypes based on CD62L expression. No data are available regarding the correlation between eosinophils subphenotypes and clinical severity of asthma, as well as the effect of anti‐IL‐5 therapy on these cells. The study investigates the correlation between blood CD62L low inflammatory eosinophils (iEos) and clinical severity of severe eosinophilic asthma (SEA) and evaluates the impact of mepolizumab on iEos. Methods 112 patients were screened and were divided in two groups: biological‐naive ( n = 51) and biological‐treated patients ( n = 61). The Biological‐naive patients were analyzed before treatment (Group A) and 19 out of 51 patients, were longitudinally analyzed before and after treatment with mepolizumab 100 mg s.c/4 weeks (Group B); 32 patients were excluded because they were being treated with other biological therapies. Blood eosinophils were analyzed by FACS and correlated with clinical scores. In vitro effect of IL‐5 and mepolizumab on CD62L expression was assessed. Results A significant correlation between blood CD62L low cells and clinical scores of asthma and nasal polyps, as well as the number of asthma exacerbations in the last year was shown in untreated patients. In longitudinally studied patients we observed a marked reduction of CD62L low cells paralleled by an increase in the proportion of CD62L bright cells, associated with clinical improvement of asthma control. In vitro, CD62L expression on eosinophils is modulated by IL‐5 and anti‐IL‐5. Conclusion A positive correlation between CD62L low iEos and the baseline clinical features of SEA with CRSwNP was shown. Furthermore mepolizumab restores the healthy balance among eosinophils sub‐phenotypes in SEA patients.
High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate
Authors: Peng Zhou, Wen-yi Chang, De-ao Gong, Jie Xia, Wei Chen, Lu-yi Huang, Rui Liu, Yi Liu, Chang Chen, Kai Wang, Ni Tang, Ai-long Huang
Journal: Cell Metabolism (2023)
Perceptions, Definitions, and Therapeutic Interventions for Occasional Constipation: A Rome Working Group Consensus Document
Authors: Darren M. Brenner, Maura Corsetti, Douglas Drossman, Jan Tack, Arnold Wald
Journal: Clinical Gastroenterology and Hepatology (2023)

Functional constipation is the most common of the disorders of gut-brain interaction, affecting approximately 12% of the world population. Although classically considered a chronic condition, many individuals experience shorter yet repetitive bouts of constipation representing a different clinical entity. There has been increased interest in this latter disorder, which has recently been classified as occasional constipation. This Rome Foundation working group document reflects the consensus of an international team of specialists who summarized currently available research to provide a working definition of and treatment algorithm for occasional constipation. The recommendations herein are based on current evidence, accounting for gaps in the literature as well as international variance in definitions and health seeking behaviors for constipation.
Targeting Hippo signaling in cancer: novel perspectives and therapeutic potential
Authors: Liemei Lv, Xiangxiang Zhou
Journal: MedComm (2023)

As highly conserved among diverse species, Hippo signaling pathway regulates various biological processes, including development, cell proliferation, stem cell function, tissue regeneration, homeostasis, and organ size. Studies in the last two decades have provided a good framework for how these fundamental functions of Hippo signaling are tightly regulated by a network with numerous intracellular and extracellular factors. The Hippo signaling pathway, when dysregulated, may lead to a wide variety of diseases, especially cancer. There is growing evidence demonstrating that dysregulated Hippo signaling is closely associated with tumorigenesis, cancer cell invasion, and migration, as well as drug resistance. Therefore, the Hippo pathway is considered an appealing therapeutic target for the treatment of cancer. Promising novel agents targeting the Hippo signaling pathway for cancers have recently emerged. These novel agents have shown antitumor activity in multiple cancer models and demonstrated therapeutic potential for cancer treatment. However, the detailed molecular basis of the Hippo signaling-driven tumor biology remains undefined. Our review summarizes current advances in understanding the mechanisms by which Hippo signaling drives tumorigenesis and confers drug resistance. We also propose strategies for future preclinical and clinical development to target this pathway.
Beyond the usual suspects: Reviewing infections caused by typically-commensal Neisseria species
Authors: Lloyd Walsh, Stephen A. Clark, Jeremy P. Derrick, Ray Borrow
Journal: Journal of Infection (2023)

Few data outside of individual case reports are available on non-meningococcal, non-gonococcal species of Neisseria as causative agents of invasive disease. This review collates disease, organism and patient information from case reports on the topic.
Reply to Wu et al's US SEER analysis of sepsis in Black patients with CTCL
Authors: Madeline J. Hooper, Francesca L. Veon, Gail L. Enriquez, Morgan Nguyen, Cameron B. Grimes, Tessa M. LeWitt, Yanzhen Pang, Slaton Case, Jaehyuk Choi, Joan Guitart, Michael B. Burns, Xiaolong A. Zhou
Journal: Journal of the American Academy of Dermatology (2023)
Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma
Authors: Guihong Wan, Bonnie W. Leung, Mia S. DeSimone, Nga Nguyen, Ahmad Rajeh, Michael R. Collier, Hannah Rashdan, Katie Roster, Xu Zhou, Cameron B. Moseley, Ajit J. Nirmal, Roxanne J. Pelletier, Zoltan Maliga, Gyorgy Marko-Varga, István Balázs Németh, Hensin Tsao, Maryam M. Asgari, Alexander Gusev, Anna M. Stagner, Christine G. Lian, Marc S. Hurlbert, Feng Liu, Kun-Hsing Yu, Peter K. Sorger, Yevgeniy R. Semenov
Journal: Journal of the American Academy of Dermatology (2023)
Recent developments in frailty identification, management, risk factors and prevention: A narrative review of leading journals in geriatrics and gerontology
Authors: Elsa Dent, Peter Hanlon, Marc Sim, Juulia Jylhävä, Zuyun Liu, Davide L. Vetrano, Erwin Stolz, Mario Ulises Pérez-Zepeda, Daniel R. Crabtree, Caroline Nicholson, Jenny Job, Rachel C. Ambagtsheer, Paul R. Ward, Sandra M. Shi, Quan Huynh, Emiel O. Hoogendijk
Journal: Ageing Research Reviews (2023)

Frailty is an age-related clinical condition characterised by an increased susceptibility to stressors and an elevated risk of adverse outcomes such as mortality. In the light of global population ageing, the prevalence of frailty is expected to soar in coming decades. This narrative review provides critical insights into recent developments and emerging practices in frailty research regarding identification, management, risk factors, and prevention. We searched journals in the top two quartiles of geriatrics and gerontology (from Clarivate Journal Citation Reports) for articles published between 01 January 2018 and 20 December 2022. Several recent developments were identified, including new biomarkers and biomarker panels for frailty screening and diagnosis, using artificial intelligence to identify frailty, and investigating the altered response to medications by older adults with frailty. Other areas with novel developments included exercise (including technology-based exercise), multidimensional interventions, person-centred and integrated care, assistive technologies, analysis of frailty transitions, risk-factors, clinical guidelines, COVID-19, and potential future treatments. This review identified a strong need for the implementation and evaluation of cost-effective, community-based interventions to manage and prevent frailty. Our findings highlight the need to better identify and support older adults with frailty and involve those with frailty in shared decision-making regarding their care.
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
Authors: E. Pujade-Lauraine, F. Selle, G. Scambia, B. Asselain, F. Marmé, K. Lindemann, N. Colombo, R. Mądry, R. Glasspool, I. Vergote, J. Korach, S. Lheureux, C. Dubot, A. Oaknin, C. Zamagni, F. Heitz, L. Gladieff, M.J. Rubio-Pérez, P. Scollo, C. Blakeley, B. Shaw, I. Ray-Coquard, A. Redondo
Journal: Annals of Oncology (2023)

Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the standard of care for some patients with advanced ovarian cancer. We evaluated the efficacy and safety of PARP inhibitor rechallenge.
Dermatology's role in the fight against human trafficking: A report from the AAD Ad Hoc Task Force and call to action
Authors: Samara Pollock, Sarah Ferree, Megan Cronin, Abigail M. Judge, Diane S. Berson, Paul M. Friedman, Pearl E. Grimes, Jenny E. Murase, Esther E. Freeman, Medha Rao, Sameer Malik, Rosie Balk, Jeffrey Miller, Terrence A. Cronin, Arianne Shadi Kourosh
Journal: Journal of the American Academy of Dermatology (2023)
Forkhead box O6 (FoxO6) promotes cardiac pathological remodeling and dysfunction by activating Kif15–TGF‐β1 under aggravated afterload
Authors: Bing Zhang, Lei Shi, Yanzhen Tan, Yenong Zhou, Jun Cui, Yujie Song, Yingying Liu, Miao Zhang, Weixun Duan, Zhenxiao Jin, Jincheng Liu, Dinghua Yi, Yang Sun, Wei Yi
Journal: MedComm (2023)

Abstract Pathological cardiac hypertrophy exhibits complex and abnormal gene expression patterns and progresses to heart failure. Forkhead box protein O6 (FoxO6) is a key transcription factor involved in many biological processes. This study aimed to explore the role of FoxO6 in cardiac hypertrophy. Three groups of mice were established: wild‐type, FoxO6 knockout, and FoxO6‐overexpressing. The mice received daily administration of angiotensin‐II (Ang‐II) or saline for 4 weeks, after which they were examined for cardiac hypertrophy, fibrosis, and function. Elevated cardiac expression of FoxO6 was observed in Ang‐II‐treated mice. FoxO6 deficiency attenuated contractile dysfunction and cardiac remodeling, including cardiomyocyte hypertrophy and fibroblast proliferation and differentiation. Conversely, FoxO6 overexpression aggravated the cardiomyopathy and heart dysfunction. Further studies identified kinesin family member 15 (Kif15) as downstream molecule of FoxO6. Kif15 inhibition attenuated the aggravating effect of FoxO6 overexpression. In vitro, FoxO6 overexpression increased Kif15 expression in cardiomyocytes and elevated the concentration of transforming growth factor‐β1 (TGF‐β1) in the medium where fibroblasts were grown, exhibiting increased proliferation and differentiation, while FoxO6 knockdown attenuated this effect. Cardiac‐derived FoxO6 promoted pathological cardiac remodeling induced by aggravated afterload largely by activating the Kif15/TGF‐β1 axis. This result further complements the mechanisms of communication among different cells in the heart, providing novel therapeutic targets for heart failure.
The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products
Authors: Gloria M Palomo, Tomas Pose-Boirazian, Frauke Naumann-Winter, Enrico Costa, Dinah M Duarte, Maria E Kalland, Eva Malikova, Darius Matusevicius, Dinko Vitezic, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska, Segundo Mariz
Journal: Molecular Therapy (2023)
Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
Authors: Alexander Neumann, Olena Ohlei, Fahri Küçükali, Isabelle J. Bos, Jigyasha Timsina, Stephanie Vos, Dmitry Prokopenko, Betty M. Tijms, Ulf Andreasson, Kaj Blennow, Rik Vandenberghe, Philip Scheltens, Charlotte E. Teunissen, Sebastiaan Engelborghs, Giovanni B. Frisoni, Oliver Blin, Jill C. Richardson, Régis Bordet, Alberto Lleó, Daniel Alcolea, Julius Popp, Thomas W. Marsh, Priyanka Gorijala, Christopher Clark, Gwendoline Peyratout, Pablo Martinez-Lage, Mikel Tainta, Richard J. B. Dobson, Cristina Legido-Quigley, Christine Van Broeckhoven, Rudolph E. Tanzi, Mara ten Kate, Christina M. Lill, Frederik Barkhof, Carlos Cruchaga, Simon Lovestone, Johannes Streffer, Henrik Zetterberg, Pieter Jelle Visser, Kristel Sleegers, Lars Bertram
Journal: Genome Medicine (2023)

Genome-wide association studies (GWAS) of Alzheimer's disease (AD) have identified several risk loci, but many remain unknown. Cerebrospinal fluid (CSF) biomarkers may aid in gene discovery and we previously demonstrated that six CSF biomarkers (β-amyloid, total/phosphorylated tau, NfL, YKL-40, and neurogranin) cluster into five principal components (PC), each representing statistically independent biological processes. Here, we aimed to (1) identify common genetic variants associated with these CSF profiles, (2) assess the role of associated variants in AD pathophysiology, and (3) explore potential sex differences.
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study
Authors: Everett E. Vokes, Francoise Mornex, Ahmet Sezer, Ying Cheng, Jian Fang, David Vicente Baz, Timucin Cil, Alex A. Adjei, Myung-Ju Ahn, Fabrice Barlesi, Enriqueta Felip, Edward B. Garon, Francois Audhuy, Rena Ito, Masashi Sato, S. Peter Eggleton, Claudio Marcelo Martin, Martin Reck, Clifford G. Robinson, Luis Paz-Ares
Journal: Journal of Thoracic Oncology (2023)

Preclinical evaluation of bintrafusp alfa (BA) combined with radiotherapy revealed greater antitumor effects than BA or radiotherapy alone. In a phase 1 study, BA exhibited encouraging clinical activity in patients with stage IIIB or IV NSCLC who had received previous treatment.